BioPharma Credit PLC Cash Flow-to-Debt Ratio
BioPharma Credit PLC cash flow-to-debt ratio. BioPharma Credit PLC (BPCR) has a Cash Flow-to-Debt Ratio of 4.50x as of June 2025, meaning its operating cash flow of $33.76 Million could theoretically repay 5% of its total liabilities ($7.49 Million) in one year. Check BPCR cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of BioPharma Credit PLC (2017–2024)
Cash flow-to-debt ratio of BioPharma Credit PLC from 2017 to 2024. Historical debt coverage capacity for BioPharma Credit PLC across 8 annual periods. Check BPCR cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
BioPharma Credit PLC Cash Flow-to-Debt Ratio by Year (2017–2024)
BioPharma Credit PLC cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for BioPharma Credit PLC. For the full cash flow conversion analysis, see BioPharma Credit PLC cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 6.24x | $111.91 Million | $17.94 Million | ▼ -19.6% |
| 2023 | 7.76x | $123.18 Million | $15.87 Million | ▲ +10.8% |
| 2022 | 7.01x | $184.28 Million | $26.30 Million | ▼ -49.9% |
| 2021 | 13.98x | $96.44 Million | $6.90 Million | ▲ +126.1% |
| 2020 | 6.18x | $58.07 Million | $9.39 Million | ▲ +18.6% |
| 2019 | 5.21x | $131.52 Million | $25.23 Million | ▲ +2.9% |
| 2018 | 5.07x | $67.14 Million | $13.25 Million | ▼ -36.0% |
| 2017 | 7.91x | $23.07 Million | $2.92 Million | — |